---
id: multimodal-clinical-data-platform
name: Multimodal clinical data platform
aliases:
  - real-world data platform
  - RWD platform
  - clinico-genomic database
  - multimodal patient data
substrate_family: A
substrate_tags:
  - A.2
enabled_by: "EHR interoperability standards, de-identification pipelines, and the cost collapse in sequencing and imaging that makes linking genomics, imaging, and claims to clinical records feasible at scale"
mechanism: "patient records, molecular profiles, imaging, and claims are harmonised, de-identified, and linked into a queryable longitudinal substrate that models and trials build on"
new_capability: "one harmonised, queryable view of the patient across EHR, genomics, imaging, and claims instead of siloed single-modality datasets"
what_it_could_unlock: "a shared data substrate that AI models, external control arms, and biomarker discovery all draw on"
capabilities:
  - capability: "harmonised real-world data at scale"
    what_it_could_unlock: "external control arms, label-expansion evidence, and post-market safety studies from real-world records"
    mechanism: "de-identified EHR, claims, and outcomes are curated and normalised into analysis-ready cohorts"
    technology_readiness_level: 8
    translational_gap: "curation is labour-heavy, coverage is US-skewed, and regulator acceptance of RWD for efficacy is uneven"
    closest_companies:
      - Flatiron Health
      - Tempus
  - capability: "linked multimodal clinico-genomic records"
    what_it_could_unlock: "biomarker discovery and virtual-cell or outcome models trained on genomics linked to real outcomes"
    mechanism: "sequencing and imaging are federated or linked to the same patient's clinical trajectory"
    technology_readiness_level: 6
    translational_gap: "cross-modality linkage, privacy, and federation across institutions remain hard and legally sensitive"
related_primitives:
  - biosimulation-qsp
  - ai-medical-imaging
  - liquid-biopsy-multiomics
  - biology-foundation-models
  - spatial-omics
use_cases:
  - external and synthetic control arms for trials
  - biomarker and target discovery on linked clinico-genomic data
  - patient stratification and companion-diagnostic development
  - post-market safety and label-expansion evidence
technology_readiness_level: 8
evidence_level: real_world_proven
translational_gap: "single-modality RWD is commercially proven, but genuinely linked multimodal records at scale are rarer, curation is expensive and manual, coverage skews US, and privacy plus federation limit how far data can be pooled"
what_needs_to_happen: "cheaper automated curation, cross-institution federation that satisfies privacy law, and clearer regulator standards for RWD-derived efficacy evidence"
closest_companies:
  - Tempus
  - Flatiron Health
  - Verily
  - Owkin
closest_labs:
  - academic medical-informatics and federated-learning groups
commercialisation_status: commercial_scaled
regulatory_complexity: high
capex_intensity: high
defensibility: high
notes: "Flatiron (oncology RWD) and Tempus (clinico-genomic) are the scaled players; Owkin adds federated multimodal learning across hospitals. The scarce asset is linked, curated multimodal data, not single-modality volume."
scan:
  bucket: hot-but-under-patented
  paper_cagr_pct: 58.1
  mean_fwci: 3.02
  industry_share: 1.0
  patent_total: 29
  patent_cagr_pct: null
  company_share: 0.731
  as_of: '2026-07-07'
last_verified: "2026-07-07"
---

## Mechanism

A multimodal clinical data platform turns scattered patient records into a single queryable substrate. It ingests electronic health records, genomic and molecular profiles, medical imaging, and claims, de-identifies them, and harmonises them onto common schemas so that one patient's clinical trajectory, sequencing, and imaging can be analysed together. Some platforms centralise the data; others (federated designs) keep it inside each hospital and move the model to the data to satisfy privacy constraints.

## What it unlocks

A shared foundation the rest of the stack builds on. Harmonised real-world data supports external and synthetic control arms, post-market safety, and label-expansion evidence. Linked clinico-genomic records power biomarker discovery, patient stratification, companion-diagnostic development, and outcome models that need genomics tied to what actually happened to the patient. Foundation models and biosimulation both consume this layer, which is why owning it is strategically valuable.

## Translational gap

The honest TRL is 8: single-modality real-world data (Flatiron in oncology, claims databases) is commercially proven and cited in regulatory contexts. The gap is genuinely linked multimodal records at scale. Curation is still labour-heavy and manual, coverage skews toward US institutions, and privacy law plus institutional federation limit how far data can be pooled. Regulator acceptance of RWD for efficacy claims is uneven rather than settled. Progress needs cheaper automated curation, privacy-preserving federation across institutions, and clearer standards for RWD-derived evidence.

## Notes

The moat is the linked, curated multimodal asset, not raw single-modality volume, which is why Owkin's federated approach and Tempus's clinico-genomic linkage matter more than record count alone. Feeds `biosimulation-qsp`, `biology-foundation-models`, and biomarker or imaging primitives downstream.
